List of Major Drug Patent Expirations Happening in 2019

Healthcare News

List of Major Drug Patent Expirations Happening in 2019

Diabetes.Hypertension.Stroke
RxSaver Editors
By RxSaver Editors
Jan 28, 2019
List of Major Drug Patent Expirations Happening in 2019

With every year that passes, more and more brand drug patent expirations occur. This year is no different. Some major drugs will lose patent protections in 2019, paving the way for generic alternatives and lower prices.

The patents for medications typically last for around 20 years after the initial application date. Patent protection can vary by how the drug is marketed. For example, a drug may lose its patent protection for certain treatments, but may maintain it for a longer period of time when it relates to other treatments.

Save Up to 80% on Your Prescriptions

Updated on January 24, 2019, based on this list of drug patent expirations.

Here are the major drug patent expirations for 2019


SYMLIN

Generic name: pramlintide acetate

Patent Expiration / Generic Entry Opportunity: March 16, 2019

Use: Symlin can help control blood sugar in people with diabetes. It’s always used with insulin.


TECFIDERA

Generic name: dimethyl fumarate

Patent Expiration / Generic Entry Opportunity: April 01, 2019

Use: Tecfidera is a fumaric acid ester used to treat relapsing forms of multiple sclerosis (MS).


FLECTOR

Generic name: diclofenac epolamine

Patent Expiration / Generic Entry Opportunity: April 13, 2019

Use: Flector can be used as a pain reliever indicated for the topical treatment of acute pain due to minor strains, sprains and contusions.


CETROTIDE

Generic name: cetrorelix

Patent Expiration / Generic Entry Opportunity: April 23, 2019

Use: Cetrotide can prevent premature ovulation in women undergoing fertility treatments with controlled ovulation.


OMTRYG

Generic name: omega-3-acid ethyl esters type a

Patent Expiration / Generic Entry Opportunity: April 23, 2019

Use: Omtryg are used together with diet and exercise to help lower triglyceride levels in the blood.


BEVESPI AEROSPHERE

Generic name: formoterol fumarate; glycopyrrolate

Patent Expiration / Generic Entry Opportunity: April 25, 2019

Use: Bevespi Aerosphere works two ways to help open airways and keep them open.


OTOVEL

Generic name: ciprofloxacin hydrochloride; fluocinolone acetonide

Patent Expiration / Generic Entry Opportunity: April 29, 2019

Use: Otovel is used to treat a type of middle ear infection in children called acute otitis media with tympanostomy tubes (AOMT) caused by certain bacteria.


BYVALSON

Generic name: nebivolol hydrochloride; valsartan

Patent Expiration / Generic Entry Opportunity: June 3, 2019

Use: Byvalson (Nebivolol & Valsartan) is a combination medicine used to treat high blood pressure (hypertension) in adults.


RESCRIPTOR

Generic name: delavirdine mesylate

Patent Expiration / Generic Entry Opportunity: June 7, 2019

Use: Rescriptor can treat HIV, the infection that causes AIDS. It doesn’t cure HIV or AIDS, but combinations of drugs that treat HIV infection may slow the disease progress and prolong life.


NATROBA

Generic name: spinosad

Patent Expiration / Generic Entry Opportunity: June 22, 2019

Use: Natroba topical suspension is used to treat head lice in adults and children who are at least 6 months old.


KOVANAZE

Generic name: oxymetazoline hydrochloride; tetracaine hydrochloride

Patent Expiration / Generic Entry Opportunity: June 29, 2019

Use: Kovanaze is a nasal spray used as dental anesthesia.


FIRAZYR

Generic name: icatibant acetate

Patent Expiration / Generic Entry Opportunity: July 15, 2019

Use: Firazyr can treat sudden attacks of hereditary angioedema (HAE).


NOXAFIL

Generic name: posaconazole

Patent Expiration / Generic Entry Opportunity: July 19, 2019

Use: Noxafil can treat or prevent fungal infections, especially in people with weak immune systems.


CARDIOTEC

Generic name: Folic Acid-C-B6-B12-E-Arginine

Patent Expiration / Generic Entry Opportunity: July 28, 2019

Use: Cardiotec is used for nutritional support and dietary supplementation.


TROXYCA ER

Generic name: naltrexone hydrochloride; oxycodone hydrochloride

Patent Expiration / Generic Entry Opportunity: August 19, 2019

Use: Troxyca ER is an extended release capsule formulation of oxycodone combined with naltrexone.


YOSPRALA

Generic name: aspirin; omeprazole

Patent Expiration / Generic Entry Opportunity: September 14, 2019

Use: Yosprala is a prescription medicine used in people who have had heart problems or strokes caused by blood clots, to help reduce their risk of further heart problems or strokes, and who are at risk of developing stomach ulcers with aspirin.


CYSTARAN

Generic name: cysteamine hydrochloride

Patent Expiration / Generic Entry Opportunity: October 2, 2019

Use: Cystaran can prevent the buildup of cystine crystals in the kidneys in its oral form. Other forms can treat cystine crystal buildup in the eye (cystinosis).


LUMASON

Generic name: sulfur hexafluoride lipid-type a microspheres

Patent Expiration / Generic Entry Opportunity: October 10, 2019

Use: Lumason (sulfur hexafluoride lipid-type A microspheres) is an ultrasound contrast agent indicated for use in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms, and in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients.


SYNRIBO

Generic name: omacetaxine mepesuccinate

Patent Expiration / Generic Entry Opportunity: October 26, 2019

Use: Synribo is used for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia.


IONSYS

Generic name: fentanyl hydrochloride

Patent Expiration / Generic Entry Opportunity: November 02, 2019

Use: Ionsys is used to treat severe pain.


SIMBRINZA

Generic name: brimonidine tartrate; brinzolamide

Patent Expiration / Generic Entry Opportunity: December 13, 2019

Use: Brimonidine and brinzolamide ophthalmic can reduce the amount of fluid in the eye, which decreases pressure inside the eye.


DUREZOL

Generic name: difluprednate

Patent Expiration / Generic Entry Opportunity: July 19, 2019

Use: Durezol can treat eye irritation and inflammation.

RxSaver Editors

RxSaver Editors

RxSaver Editors are wellness enthusiasts who help you learn how you can save the most on prescription medication costs and other health-related topics.

The information on this site is generalized and is not medical advice. It is intended to supplement, not substitute for, the expertise and judgment of your healthcare professional. Always seek the advice of your healthcare professional with any questions you may have regarding a medical condition. Never disregard seeking advice or delay in seeking treatment because of something you have read on our site. RxSaver makes no warranty as to the accuracy, reliability or completeness of this information.

If you are in crisis or you think you may have a medical emergency, call your doctor or 911 immediately.